A micro-engineered “tumor-on-a-chip” that mimics the living ecosystem of pancreatic cancer has exposed a treacherous alliance between tumors and the body’s own immune cells. Instead of killing cancer, a specific population of myeloid-derived suppressor cells (MDSCs) actively remodels the tumor microenvironment into an inflammatory fortress, researchers report. The real-time observations, made possible by a new microfluidic platform, reveal a self-reinforcing feedback loop that could explain why pancreatic cancer remains one of the most lethal malignancies, with five-year survival rates hovering around 12 percent. By watching this betrayal unfold live, scientists have identified both a previously hidden reservoir of fibroblast precursor cells poised to turn inflammatory and a suite of signaling pathways that may serve as therapeutic targets to dismantle the tumor’s defenses.
Pancreatic tumors are notoriously difficult to treat in part because they are enmeshed in a dense, desmoplastic stroma—a thick matrix of structural proteins, fibroblasts, and immune cells that acts as both a physical barrier and a biochemical support network. Within this milieu, cancer-associated fibroblasts (CAFs) are not passive scaffolding; they secrete growth factors, remodel the extracellular matrix, and crosstalk with infiltrating immune cells. The new study, published in Biofabrication, focused on the inflammatory subset of CAFs, known as iCAFs, which can suppress anti-tumor immunity and promote angiogenesis. Until now, capturing the dynamic transitions that convert resting fibroblasts into iCAFs, and the role of immune cells in that conversion, has been beyond the reach of conventional two-dimensional cultures or static organoid models.
The Sylvester Comprehensive Cancer Center team, led by biomedical engineer Ashutosh Agarwal and pancreatic surgical oncologist Jashodeep Datta, engineered a handheld microfluidic device that integrates three-dimensional pancreatic cancer tissue with a flowing stream of immune cells. The chip recreates the shear forces, nutrient gradients, and cellular trafficking patterns found in a living pancreas. Using live-cell imaging and transcriptomic profiling, the researchers watched as MDSCs infiltrated the tumor-like constructs and triggered a striking phenotypic switch in fibroblasts. Within 48 hours, a significant fraction of fibroblasts upregulated the inflammatory markers IL-6, LIF, and CXCL1, effectively transforming into iCAFs. Most importantly, the activated iCAFs then secreted their own chemoattractants, recruiting even more MDSCs and locking the system into a vicious cycle.
A serendipitous finding emerged from single-cell RNA sequencing performed on fibroblasts isolated from the chip at early time points. The team discovered a previously underappreciated transitional fibroblast state—cells that had not yet adopted inflammatory signatures but were already primed with open chromatin at key enhancer regions of iCAF-associated genes. Under the influence of MDSC-derived cytokines, particularly interleukin-1α and tumor necrosis factor, these poised cells rapidly completed their epigenetic programming and became full-fledged iCAFs. “These cells are already on the path toward becoming pro-inflammatory, and the immune system accelerates that transformation,” Agarwal noted. This precursor population, which the group calls pre-iCAFs, represents a new cellular target that static tumor analyses would likely miss.
The implications for therapy extend beyond pancreatic cancer. Many solid malignancies deploy similar stromal-immune crosstalk to create immunologically cold microenvironments that resist checkpoint inhibitors and CAR-T cell therapies. By interrupting the communication channels identified in this platform—such as blocking IL-1α signaling with existing anti-inflammatory agents—it may be possible to prevent the conversion of pre-iCAFs and deplete the pool of inflammation-driving fibroblasts. The microfluidic chip itself offers a versatile platform for rapid screening of such interventions, potentially predicting patient-specific responses before clinical trials.
The platform’s ability to deconstruct a complex ecosystem into controllable variables also allowed the researchers to demonstrate causality. When they selectively depleted MDSCs from the circulating immune mix, the fibroblasts remained quiescent. Reintroducing MDSCs, but not other myeloid populations, restored the inflammatory cascade. This elegant experimental design shifts the role of MDSCs from passive immunosuppressors to active directors of tissue remodeling, cementing their status as a high-priority therapeutic target. Testing in patient-derived tissue slices is already underway, and preliminary data suggest that heterogeneity in pre-iCAF abundance may correlate with aggressive disease, potentially offering a new prognostic biomarker.
While the current study focused on pancreatic ductal adenocarcinoma, the underlying principles of stromal-immune co-evolution likely extend to other stroma-rich cancers, including breast and colorectal tumors. The technology also opens a window into studying chronic inflammatory diseases such as pancreatitis or rheumatoid arthritis, where analogous fibroblast-immune loops drive tissue destruction. As the lines between cancer biology, immunology, and engineering continue to blur, tumor-on-a-chip systems are poised to become a cornerstone of translational oncology—transforming how we watch, decode, and ultimately dismantle cancer’s most devious survival strategies.
Subject of Research: Immune-driven stromal inflammation in pancreatic cancer within a microfluidic platform
Article Title: Immune-driven stromal inflammation in pancreatic cancer within a microfluidic platform
News Publication Date: July 6, 2026
Web References:
- Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center
- InventUM blog: https://news.med.miami.edu/pancreatic-cancer-tumor-on-a-chip-immune-system/
- Ashutosh Agarwal profile: https://people.miami.edu/profile/e6d843b487331b68d3370c8cdde82bcd
- Jashodeep Datta profile: https://med.miami.edu/faculty/jashodeep-datta-md
References: DOI: 10.1088/1758-5090/ae7b09
Image Credits: Sylvester Comprehensive Cancer Center
Keywords: Pancreatic cancer, tumor-on-a-chip, microfluidics, tumor microenvironment, myeloid-derived suppressor cells, cancer-associated fibroblasts, inflammatory CAFs, immune evasion, biofabrication, IL-1 signaling
